Prostate Cancer
Conditions
Brief summary
This study is evaluating the efficacy of cabazitaxel and hormonal treatment as neoadjuvant treatment for patients with clinically operable disease suitable for surgery, and a high risk of relapse after surgery
Detailed description
This study is evaluating the efficacy of cabazitaxel and hormonal treatment (LHRH analogues) as neoadjuvant treatment for patients with clinically operable disease suitable for surgery (no lymph node, visceral or bony metastases), and a high risk of relapse after surgery (5 year risk of relapse). Patients will receive four cycles of neoadjuvant treatment (cabazitaxel treatment and 3 months LHRH treatment) unless there is evidence of disease progression, unacceptable toxicity or patient request to withdraw consent.
Interventions
DRUGCabazitaxel
Patients will receive Cabazitaxel 25 mg/m2 \* intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment. \*Cabazitaxel dose should be capped at 50mg (BSA=2)
Sponsors
University of Liverpool
The Clatterbridge Cancer Centre NHS Foundation Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A two arm, phase II randomised multi-centre trial. 120 patients will be recruited to the trial. Patients will be randomised to a control arm of immediate surgery or a treatment arm in a ratio of 1:2 (control 40pts: treatment 80pts). Patients in the treatment arm will receive hormonal treatment and Cabazitaxel 25 mg/m2 day 1 intravenously over one hour every 21 days. Treatment will be continued for 4 cycles (3 months) unless disease progression, unacceptable toxicity or patient request.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged ≥18 years 2. ECOG performance status 0-1 (Appendix 2) 3. Diagnosis of high risk prostate cancer as defined by one or more of the following: clinically T2c/T3, Gleason 8-10 and or PSA \>10ng/ml 4. Appropriate candidate for radical prostatectomy 5. Life expectancy greater than 10 years 6. Adequate organ function as evidenced by peripheral blood counts and serum chemistries at enrolment 7. Ability and capacity to consent and comply with study and follow-up procedures 8. Fit to receive chemotherapy
Exclusion criteria
1. Locally advanced or metastatic disease 2. Patients with a history of other previous malignancy except treated CIN or non melanomatous skin cancer 3. Grade ≥2 peripheral neuropathy 4. Grade ≥2 stomatitis 5. History of severe hypersensitivity reaction (≥ grade 3) to taxane 6. History of severe hypersensitivity reaction (≥ grade 3) to polysorbate 80 containing drugs 7. Other concurrent serious illness or medical conditions 8. Inadequate organ and bone marrow function as evidenced by: 1. Haemoglobin \<10.0 g/dL 2. Absolute neutrophil count \<1.5 x 109/L 3. Platelet count \<100 x 109/L 4. AST/SGOT and/or ALT/SGPT \>1.5 xULN 5. Total bilirubin \>1.5 x ULN 6. Serum creatinine \>1.5 x ULN (if creatinine is 1.0 - 1.5 xULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \<60mL/min should be excluded - see Appendix 3) 9. Uncontrolled diabetes mellitus 10. Active uncontrolled gastro oesophageal reflux disease (GORD) 11. Active infection requiring systemic antibiotic or antifungal medication 12. Participation in another clinical trial with any investigational drug within 30 days prior to study enrolment 13. Concurrent or planned treatment with strong inhibitors of cytochrome P450 3A4/5 (a 1-week washout period is necessary for patients who are already on these treatments - see Appendix 5 for a list of CYP3A inhibitors) 14. Concurrent or planned treatment with strong inducers of cytochrome P450 3A4/5 (a 1-week washout period is necessary for patients who are already on these treatments) - see Appendix 4 for a list of CYP3A inducers) 15. Contraindications or sensitivity to GCSF treatments 16. History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of Grade \> 2 (NCI CTCAE, version 4.03), thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 6 months prior to first dose of study drug. Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess the efficacy activity of neoadjuvant Cabazitaxel chemotherapy and hormonal therapy in patients with high risk operable prostate cancer, measuring the reduction in treatment failure and comparing this to that obtained in the control arm | through study completion, average 3 years | Treatment failure is defined as: PSA level ≥ 0.12ng/ml measured on at least two occasions (1 confirmatory sample) post-surgery within three years of follow-up or death related to prostate cancer or use of a salvage therapy or not undergoing surgery at all.) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess the efficacy of neoadjuvant Cabazitaxel chemotherapy and hormonal therapy, assessing surgical margin involvement and comparing this to that obtained in a control arm of immediate surgery. | 3 year follow up | The proportion of patients with positive resection margin will be reported and compared across the treatment groups using Chi-square tests. Multivariable models using logistic regression techniques shall be used to adjust for key prognostic variables of interest. |
| To assess the efficacy of neoadjuvant Cabazitaxel chemotherapy and hormonal therapy, assessing lymph node involvement and comparing this to that obtained in a control arm of immediate surgery. | 3 year follow up | The proportion of patients with positive lymph nodes will be reported and compared across the treatment groups using Chi-square tests. |
| To assess the efficacy of neoadjuvant Cabazitaxel chemotherapy and hormonal therapy, measuring progression free survival and comparing this to that obtained in a control arm of immediate surgery. | 3 year follow up | — |
| • To assess the efficacy of neoadjuvant Cabazitaxel chemotherapy and hormonal therapy, measuring the pathological and radiological response rates and comparing this to that obtained in a control arm of immediate surgery. | 3 year follow up | Pathological response rate assessed as per pTNM staging system Radiological response rates as defined in RECIST V1.1 Combined to give overall response rate |
| To assess the efficacy of neoadjuvant Cabazitaxel chemotherapy and hormonal therapy, measuring surgical feasibility and comparing this to that obtained in a control arm of immediate surgery. | 3 year follow up | The proportion of patients with delays to surgery, perioperative morbidities, mortalities and surgical complications will be reported and compared across the treatment groups. |
| To assess the quality of life of patients receiving neoadjuvant Cabazitaxel chemotherapy and hormonal therapy and comparing this to quality of life patients in a control arm of immediate surgery using the EORTC QLQ-C30 version 3 questionnaire. | 3 year follow up | Responses to EORTC QLQ-C30 will be reported (median, IQR) according to global health status, the functional scales and symptom scales, by intervention group, and over time. Joint modelling or quality-adjusted survival analysis will be undertaken to allow a simultaneous assessment of quality of life and survival. |
| • To assess the efficacy of neoadjuvant Cabazitaxel chemotherapy and hormonal therapy, measuring overall survival from time of randomisation to death and comparing this to that obtained in a control arm of immediate surgery. | 3 year follow up | — |
Contacts
Primary ContactMarie Maguire
Backup ContactClaire Taylor
Outcome results
None listed